Laboratorios Farmacéuticos ROVI - Investing for future growth
Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26% and EBITDA margin expansion of 620bp to 16.0%. Total revenues of €382.5m were driven by its low molecular weight heparin (LMWH) franchise (Becat and Hibor) and toll manufacturing business. Becat (enoxaparin biosimilar) and flagship drug Hibor (bemiparin) reported combined sales of €177.6m (+46%). ROVI has consolidated its toll manufacturing units into a single entity; this division grew 20% in 2019 (€65.6m). Management has guided to mid-single digit growth in total operating revenues for 2020, which seems conservative. The MAA for DORIA has now been filed with the EMA (January 2020) and the NDA filing with the FDA is expected in H220. We value ROVI at €1.49bn.Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.